Skip to main content

Mokari Atabak's Form 4 filing

Corcept Therapeutics Inc (CORT) · filed Aug 3, 2026

Accession no.
0001193125-26-330668
Filed
Aug 3, 2026, 4:30 PM ET
Trade date
Jul 30, 2026
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 14 non-derivative transactions and 1 derivative transaction. Open-market sales total $9.18M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mokari AtabakCIK 0001678419Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 30, 2026Common StockMOption exerciseAcquired+80,000$23.06+$1,844,80096,130Direct
Jul 30, 2026Common StockSSaleDisposed−4,200$105.54F3−$443,247.8491,930Direct
Jul 30, 2026Common StockSSaleDisposed−8,956$106.96F4−$957,891.6782,974Direct
Jul 30, 2026Common StockSSaleDisposed−400$108.46−$43,38482,574Direct
Jul 30, 2026Common StockSSaleDisposed−2,202$110.03F5−$242,282.3280,372Direct
Jul 30, 2026Common StockSSaleDisposed−600$110.95−$66,57079,772Direct
Jul 30, 2026Common StockSSaleDisposed−4,700$113.18F6−$531,940.8375,072Direct
Jul 30, 2026Common StockSSaleDisposed−15,477$114.96F7−$1,779,237.4759,595Direct
Jul 30, 2026Common StockSSaleDisposed−14,222$115.87F8−$1,647,859.0545,373Direct
Jul 30, 2026Common StockSSaleDisposed−7,089$116.96F9−$829,101.7938,284Direct
Jul 30, 2026Common StockSSaleDisposed−8,267$117.93F10−$974,951.2830,017Direct
Jul 30, 2026Common StockSSaleDisposed−4,783$118.73F11−$567,907.5925,234Direct
Jul 30, 2026Common StockSSaleDisposed−8,103$119.95F12−$971,939.4517,131Direct
Jul 30, 2026Common StockSSaleDisposed−1,001$120.67F13−$120,795.5716,130Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 30, 2026Common StockMOption exerciseDisposed−80,000$0.00$095,833Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $105.305 to $106.2 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F4

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $106.75 to $107.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F5

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.71 to $110.42 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F6

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.96 to $113.89 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F7

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.305 to $115.30 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F8

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.35 to $116.27 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F9

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.35 to $117.3 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F10

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.41 to $118.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F11

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.42 to $119.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F12

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.42 to $120.41 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F13

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $120.49 to $120.84 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

Remarks

The power of attorney under which this form was signed is on file with the Commission.

Read the full filing on SEC EDGAR (opens in a new tab)